Neha J Pagidipati, Adam J Nelson, Lisa A Kaltenbach, Monica Leyva, Darren K McGuire, Rodica Pop-Busui, Matthew A Cavender, Vanita R Aroda, Melissa L Magwire, Caroline R Richardson, Ildiko Lingvay, Julienne K Kirk, Hussein R Al-Khalidi, Laura Webb, Tanya Gaynor, Jonathan Pak, Cagri Senyucel, Renato D Lopes, Jennifer B Green, Christopher B Granger
IMPORTANCE: Evidence-based therapies to reduce atherosclerotic cardiovascular disease risk in adults with type 2 diabetes are underused in clinical practice. OBJECTIVE: To assess the effect of a coordinated, multifaceted intervention of assessment, education, and feedback vs usual care on the proportion of adults with type 2 diabetes and atherosclerotic cardiovascular disease prescribed all 3 groups of recommended, evidence-based therapies (high-intensity statins, angiotensin-converting enzyme inhibitors [ACEIs] or angiotensin receptor blockers [ARBs], and sodium-glucose cotransporter 2 [SGLT2] inhibitors and/or glucagon-like peptide 1 receptor agonists [GLP-1RAs])...
April 18, 2023: JAMA